CA3013467A1 - Compositions containing tucaresol or its analogs - Google Patents

Compositions containing tucaresol or its analogs Download PDF

Info

Publication number
CA3013467A1
CA3013467A1 CA3013467A CA3013467A CA3013467A1 CA 3013467 A1 CA3013467 A1 CA 3013467A1 CA 3013467 A CA3013467 A CA 3013467A CA 3013467 A CA3013467 A CA 3013467A CA 3013467 A1 CA3013467 A1 CA 3013467A1
Authority
CA
Canada
Prior art keywords
cancer
alpha
inhibitor
immune checkpoint
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3013467A
Other languages
English (en)
French (fr)
Inventor
Lan Huang
Ramon Mohanlal
George Kenneth Lloyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59563990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3013467(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Publication of CA3013467A1 publication Critical patent/CA3013467A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3013467A 2016-02-08 2017-02-06 Compositions containing tucaresol or its analogs Pending CA3013467A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662292763P 2016-02-08 2016-02-08
US62/292,763 2016-02-08
PCT/US2017/016740 WO2017139231A1 (en) 2016-02-08 2017-02-06 Compositions containing tucaresol or its analogs

Publications (1)

Publication Number Publication Date
CA3013467A1 true CA3013467A1 (en) 2017-08-17

Family

ID=59563990

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013467A Pending CA3013467A1 (en) 2016-02-08 2017-02-06 Compositions containing tucaresol or its analogs

Country Status (18)

Country Link
US (2) US10912748B2 (enExample)
EP (1) EP3413885A4 (enExample)
JP (2) JP2019511565A (enExample)
KR (1) KR20180105685A (enExample)
CN (1) CN108778267A (enExample)
AU (1) AU2017217426B2 (enExample)
BR (1) BR112018016054A2 (enExample)
CA (1) CA3013467A1 (enExample)
CO (1) CO2018009096A2 (enExample)
EC (1) ECSP18067631A (enExample)
IL (1) IL260933B2 (enExample)
MX (1) MX388474B (enExample)
MY (1) MY192703A (enExample)
NZ (1) NZ744854A (enExample)
PH (1) PH12018501669A1 (enExample)
RU (1) RU2753543C1 (enExample)
SG (1) SG11201806583XA (enExample)
WO (1) WO2017139231A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170117113A (ko) * 2015-02-12 2017-10-20 비욘드스프링 파마수티컬스, 인코포레이티드. 면역 관문 저해제와 조합한 플리나불린의 용도
MY194341A (en) 2015-03-06 2022-11-29 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
CA2978567A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a ras mutation using plinabulin
MX376122B (es) 2015-07-13 2025-03-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
CN110381938A (zh) 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
DK3595653T3 (da) * 2017-03-13 2023-04-17 Beyondspring Pharmaceuticals Inc Sammensætninger af plinabulin og anvendelse heraf
CN109420167B (zh) * 2017-08-28 2022-02-11 四川九章生物科技有限公司 一种治疗肿瘤的联合用药物
SG11202006985TA (en) 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin
KR20210131316A (ko) 2019-02-27 2021-11-02 밀레니엄 파머슈티컬스 인코퍼레이티드 Sumo-활성화 효소 저해제 및 관문 저해제의 투여
MX2021010993A (es) * 2019-03-14 2021-12-10 Engene Inc Expresión localizada de il-12 basada en poliplex de quitosano sola o en combinación con inductores de ifn tipo i para el tratamiento de cánceres mucosos.
MX2022002607A (es) * 2019-09-03 2022-03-25 Intra Cellular Therapies Inc Metodos de tratamiento.
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
WO2021225908A1 (en) * 2020-05-04 2021-11-11 Beyondspring Pharmaceuticals, Inc. Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA803880B (en) * 1979-06-29 1982-02-24 Wellcome Found Pharmaceutical ethers,preparation,use and intermediates therefor and their preparation
HU190371B (en) 1980-12-18 1986-08-28 The Wellcome Foundation Ltd,Gb Process for producing ether-type compounds and pharmaceutical compositions containing them as active agents
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
DK0609606T3 (enExample) * 1992-10-01 1997-03-17 Wellcome Found
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
US6096786A (en) * 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
DK0674510T3 (da) 1992-11-27 1999-05-10 Napro Biotherapeutics Inc Injicerbart præparat omfattende paclitaxel
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) * 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
US6479484B1 (en) 1997-11-21 2002-11-12 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
PL342254A1 (en) 1998-01-29 2001-06-04 Aventis Pharm Prod Inc Method of obtaining n-[(aliphatic or aromatic substituend)carbonyl)]-2-aminacetamide and cyclised compound
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
CN1142909C (zh) 1998-03-26 2004-03-24 盐野义制药株式会社 具有抗病毒活性的吲哚衍生物
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6972289B1 (en) 2000-01-18 2005-12-06 Nereus Pharmaceuticals, Inc. Cell division inhibitor and a production method thereof
CA2403553A1 (en) 2000-03-17 2001-09-27 David Johnson Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
EP1282609B1 (en) 2000-05-09 2008-12-17 AngioRx Corporation Piperazinedione compounds
WO2002064592A1 (en) 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
RS96304A (sr) 2002-05-17 2006-10-27 Aventis Pharma S.A. Primena docetaksel/doksorubicin/ ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
KR101049100B1 (ko) 2002-08-02 2011-07-15 니리어스 파마슈티컬즈, 인코퍼레이션 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의 합성방법
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
JP2007520565A (ja) 2004-02-04 2007-07-26 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成
EP1740593B1 (en) 2004-04-19 2016-04-06 KRKA, tovarna zdravil, d.d., Novo mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
EP2007423A2 (en) * 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2481418A1 (en) * 2007-02-15 2012-08-01 MannKind Corporation A method for enhancing T cell response
CN101678078B (zh) 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2962731A1 (en) 2008-01-08 2016-01-06 Bristol-Myers Squibb Company Combination of ipilimumab and paclitaxel for the treatment of cancer
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
CA2749802C (en) 2009-01-16 2016-08-23 Teva Pharmaceutical Industries Ltd. New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
SG178828A1 (en) 2009-08-10 2012-04-27 Univ Texas Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
MX366955B (es) 2009-09-15 2019-07-31 Bluelink Pharmaceuticals Inc Crlx101 para usarse en el tratamiento de cáncer.
WO2011050344A2 (en) * 2009-10-23 2011-04-28 Mannkind Corporation Cancer immunotherapy and method of treatment
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
US20130225424A1 (en) 2010-03-03 2013-08-29 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
WO2011146382A1 (en) 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
EP2576514A1 (en) 2010-06-04 2013-04-10 Exonhit Sa Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
EP2646577A2 (en) 2010-11-29 2013-10-09 Precision Therapeutics Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
WO2013078537A1 (en) 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
KR102452803B1 (ko) 2012-05-09 2022-10-07 캔텍스 파마슈티칼즈, 인크. 골수억제의 치료
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
ES2760023T3 (es) 2013-02-20 2020-05-12 Univ Pennsylvania Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
EP2968536B1 (en) 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
WO2014174480A1 (en) 2013-04-24 2014-10-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
SG11201509742QA (en) 2013-06-03 2015-12-30 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2015051543A1 (en) 2013-10-11 2015-04-16 Dalian Wanchun Biotechnology Co., Ltd. Cancer treatment with combination of plinabulin and taxane
EP4461372A3 (en) * 2013-11-05 2025-01-22 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
WO2015069790A1 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for subtyping lymphoma types by means expression profiling
CN104796448B (zh) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CN106794246B (zh) * 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
KR20170117113A (ko) 2015-02-12 2017-10-20 비욘드스프링 파마수티컬스, 인코포레이티드. 면역 관문 저해제와 조합한 플리나불린의 용도
CA2978567A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a ras mutation using plinabulin
MY194341A (en) 2015-03-06 2022-11-29 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
CN106279039B (zh) 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
MX376122B (es) 2015-07-13 2025-03-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
US10912748B2 (en) * 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
CN110381938A (zh) 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
DK3595653T3 (da) 2017-03-13 2023-04-17 Beyondspring Pharmaceuticals Inc Sammensætninger af plinabulin og anvendelse heraf
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
SG11202006985TA (en) 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN112105363A (zh) 2018-02-01 2020-12-18 大连万春布林医药有限公司 用于通过施用普那布林和g-csf剂来减少化学疗法诱导的嗜中性白血球减少症的组合物和方法
CN110240592A (zh) 2018-03-08 2019-09-17 青岛海洋生物医药研究院股份有限公司 (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
JP7372253B2 (ja) 2018-04-05 2023-10-31 ノビガ・リサーチ・エービー 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ
CA3101612A1 (en) 2018-06-01 2019-12-05 Beyondspring Pharmaceuticals, Inc. Composition and method of treating cancer associated with egfr mutation
US20210177952A1 (en) 2018-08-16 2021-06-17 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
CA3119768A1 (en) 2018-11-14 2020-05-22 Beyondspring Pharmaceuticals, Inc. Methods of treating cancer using tubulin binding agents
CN112778155B (zh) 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
WO2021225908A1 (en) 2020-05-04 2021-11-11 Beyondspring Pharmaceuticals, Inc. Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity

Also Published As

Publication number Publication date
JP2019511565A (ja) 2019-04-25
AU2017217426B2 (en) 2022-12-01
AU2017217426A1 (en) 2018-08-23
KR20180105685A (ko) 2018-09-28
MX388474B (es) 2025-03-20
MY192703A (en) 2022-09-02
RU2753543C1 (ru) 2021-08-17
NZ744854A (en) 2020-01-31
PH12018501669A1 (en) 2019-06-17
CN108778267A (zh) 2018-11-09
IL260933A (en) 2018-10-31
BR112018016054A2 (pt) 2019-02-12
US20190380983A1 (en) 2019-12-19
JP2022088662A (ja) 2022-06-14
CO2018009096A2 (es) 2019-04-30
EP3413885A1 (en) 2018-12-19
SG11201806583XA (en) 2018-09-27
WO2017139231A1 (en) 2017-08-17
US20210161844A1 (en) 2021-06-03
US11857522B2 (en) 2024-01-02
IL260933B (en) 2022-12-01
US10912748B2 (en) 2021-02-09
EP3413885A4 (en) 2019-09-18
IL260933B2 (en) 2023-04-01
ECSP18067631A (es) 2018-09-30
MX2018009413A (es) 2019-05-15

Similar Documents

Publication Publication Date Title
US11857522B2 (en) Compositions containing tucaresol or its analogs
AU2021202416B2 (en) Use of plinabulin in combination with immune checkpoint inhibitors
US20230181605A1 (en) Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity
US12377094B2 (en) Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies
US20220387365A1 (en) Tucaresol derivatives and uses thereof
US20250073230A1 (en) Use of plinabulin in combination with immune checkpoint inhibitors
TW202315631A (zh) 增強低免疫原性癌症中癌細胞毒殺的三聯療法
NZ750444B2 (en) Use of plinabulin in combination with immune checkpoint inhibitors
BR112017016902B1 (pt) Composição farmacêutica, respectivo uso e uso de plinabulina

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220204

EEER Examination request

Effective date: 20220204

EEER Examination request

Effective date: 20220204

EEER Examination request

Effective date: 20220204